Venture Competitions

Venture Competitions

AIM-HI launched our Venture Competition programs to empower scientist-entrepreneurs in the oncology arena. Through these annual competition programs, AIM-HI provides critically needed seed funding, important coaching, and continuous access to our global network to highly promising scientist-entrepreneurs, thus furthering the development of groundbreaking treatments and accelerating life-saving innovations.

All submitted applications will be reviewed and screened by our Selection Committee based on the quality of applications. 6-8 semi-finalists will be chosen in early May and invited to compete in front of a Judging Committee in mid-July to select finalists. An Investment Committee will conduct detailed due diligence research on the finalists based on the technology platform merits, cancer patient impact, and potential for return on investment. The company that passes the due diligence process will be eligible to receive investment from AIM-HI and co-investors. Our three-part Selection, Judging, and Investment Committees consist of world-class life sciences industry professionals, business leaders, and investors.

Applying companies have access to a FREE, virtual legal seminar series, provided by our partner, Cooley, on topics such as Corporate Legal Basics, IP Protection for Start-Ups, Legal Pitfalls for Start-Ups to Avoid, & Life Science University Transactions/ Licensing. For more information, please contact AIM-HI Program Manager Ella Ye at eye@aim-hiaccelerator.org.

Why Should You Apply?

  • Interacting with and receiving valuable feedback from the selection and judging committee members, who are key opinion leaders in the oncology field.

  • Top winnners will be awarded honorariums, recognized with certificates, and considered for further investment, subject to rigorous due diligence conducted by our Investment Committee.

  • The winners will gain recognition and presentation opportunities within the oncology research community, facilitating networking and collaboration opportunities with global cancer experts and investors.

  • The winners who pass the due diligence process will be eligible to receive investment from AIM-HI and co-investors; the process itself will also help the company assess and refine its IP and strategy, clinical development plan, and position itself well for other investors.

In addition to seed-stage financing, AIM-HI provides other essential resources to participating startups, including: